234 related articles for article (PubMed ID: 15020289)
1. Clinical significance of breakthrough fungemia caused by azole-resistant Candida tropicalis in patients with hematologic malignancies.
Myoken Y; Kyo T; Fujihara M; Sugata T; Mikami Y
Haematologica; 2004 Mar; 89(3):378-80. PubMed ID: 15020289
[TBL] [Abstract][Full Text] [Related]
2. Breakthrough fungemia caused by fluconazole-resistant Candida albicans with decreased susceptibility to voriconazole in patients with hematologic malignancies.
Myoken Y; Kyo T; Sugata T; Murayama SY; Mikami Y
Haematologica; 2006 Feb; 91(2):287-8. PubMed ID: 16461328
[TBL] [Abstract][Full Text] [Related]
3. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy.
Hachem R; Hanna H; Kontoyiannis D; Jiang Y; Raad I
Cancer; 2008 Jun; 112(11):2493-9. PubMed ID: 18412153
[TBL] [Abstract][Full Text] [Related]
4. Breakthrough fungemia caused by azole-resistant Candida albicans in neutropenic patients with acute leukemia.
Myoken Y; Kyo T; Kohara T; Fujihara M; Sugata T; Mikami Y
Clin Infect Dis; 2003 Jun; 36(11):1496-7. PubMed ID: 12766847
[No Abstract] [Full Text] [Related]
5. Community-acquired fungemia due to a multiple-azole-resistant strain of Candida tropicalis.
Jandourek A; Brown P; Vazquez JA
Clin Infect Dis; 1999 Dec; 29(6):1583-4. PubMed ID: 10585825
[No Abstract] [Full Text] [Related]
6. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients.
Minari A; Hachem R; Raad I
Clin Infect Dis; 2001 Jan; 32(2):186-90. PubMed ID: 11170906
[TBL] [Abstract][Full Text] [Related]
7. Fatal candidemia caused by azole-resistant Candida tropicalis in patients with hematological malignancies.
Chong Y; Shimoda S; Yakushiji H; Ito Y; Miyamoto T; Shimono N; Kamimura T; Akashi K
J Infect Chemother; 2012 Oct; 18(5):741-6. PubMed ID: 22526385
[TBL] [Abstract][Full Text] [Related]
8. Candidemia in patients with hematologic malignancies: analysis of 7 years' experience in a single center.
Vigouroux S; Morin O; Moreau P; Harousseau JL; Milpied N
Haematologica; 2006 May; 91(5):717-8. PubMed ID: 16670081
[TBL] [Abstract][Full Text] [Related]
9. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection.
Sipsas NV; Lewis RE; Tarrand J; Hachem R; Rolston KV; Raad II; Kontoyiannis DP
Cancer; 2009 Oct; 115(20):4745-52. PubMed ID: 19634156
[TBL] [Abstract][Full Text] [Related]
10. Risk Factors for Candida tropicalis fungemia in patients with cancer.
Kontoyiannis DP; Vaziri I; Hanna HA; Boktour M; Thornby J; Hachem R; Bodey GP; Raad II
Clin Infect Dis; 2001 Nov; 33(10):1676-81. PubMed ID: 11568858
[TBL] [Abstract][Full Text] [Related]
11. Candidemia due to Candida tropicalis: clinical, epidemiologic, and microbiologic characteristics of 188 episodes occurring in tertiary care hospitals.
Nucci M; Colombo AL
Diagn Microbiol Infect Dis; 2007 May; 58(1):77-82. PubMed ID: 17368800
[TBL] [Abstract][Full Text] [Related]
12. Fungaemia caused by Candida glabrata with reduced susceptibility to fluconazole due to altered gene expression: risk factors, antifungal treatment and outcome.
Tumbarello M; Sanguinetti M; Trecarichi EM; La Sorda M; Rossi M; de Carolis E; de Gaetano Donati K; Fadda G; Cauda R; Posteraro B
J Antimicrob Chemother; 2008 Dec; 62(6):1379-85. PubMed ID: 18782778
[TBL] [Abstract][Full Text] [Related]
13. Do clinical features allow for accurate prediction of fungal pathogenesis in bloodstream infections? Potential implications of the increasing prevalence of non-albicans candidemia.
Shorr AF; Lazarus DR; Sherner JH; Jackson WL; Morrel M; Fraser VJ; Kollef MH
Crit Care Med; 2007 Apr; 35(4):1077-83. PubMed ID: 17312565
[TBL] [Abstract][Full Text] [Related]
14. Clinical applicability of antifungal susceptibility testing on non-Candida albicans species in hospitalized patients.
Wong-Beringera A; Hindler J; Brankovic L; Muehlbauer L; Steele-Moore L
Diagn Microbiol Infect Dis; 2001 Jan; 39(1):25-31. PubMed ID: 11173188
[TBL] [Abstract][Full Text] [Related]
15. Candida glabrata fungemia: experience in a tertiary care center.
Malani A; Hmoud J; Chiu L; Carver PL; Bielaczyc A; Kauffman CA
Clin Infect Dis; 2005 Oct; 41(7):975-81. PubMed ID: 16142662
[TBL] [Abstract][Full Text] [Related]
16. Azole resistance of Candida glabrata in a case of recurrent fungemia.
Posteraro B; Tumbarello M; La Sorda M; Spanu T; Trecarichi EM; De Bernardis F; Scoppettuolo G; Sanguinetti M; Fadda G
J Clin Microbiol; 2006 Aug; 44(8):3046-7. PubMed ID: 16891541
[TBL] [Abstract][Full Text] [Related]
17. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies.
Garcia-Effron G; Kontoyiannis DP; Lewis RE; Perlin DS
Antimicrob Agents Chemother; 2008 Nov; 52(11):4181-3. PubMed ID: 18794386
[TBL] [Abstract][Full Text] [Related]
18. Recent experience with fungaemia: change in species distribution and azole resistance.
Chakrabarti A; Chatterjee SS; Rao KL; Zameer MM; Shivaprakash MR; Singhi S; Singh R; Varma SC
Scand J Infect Dis; 2009; 41(4):275-84. PubMed ID: 19229762
[TBL] [Abstract][Full Text] [Related]
19. Oral Candida isolates in patients undergoing radiotherapy for head and neck cancer: prevalence, azole susceptibility profiles and response to antifungal treatment.
Belazi M; Velegraki A; Koussidou-Eremondi T; Andreadis D; Hini S; Arsenis G; Eliopoulou C; Destouni E; Antoniades D
Oral Microbiol Immunol; 2004 Dec; 19(6):347-51. PubMed ID: 15491459
[TBL] [Abstract][Full Text] [Related]
20. Antifungal susceptibility of 1000 Candida bloodstream isolates to 5 antifungal drugs: results of a multicenter study conducted in São Paulo, Brazil, 1995-2003.
da Matta DA; de Almeida LP; Machado AM; Azevedo AC; Kusano EJ; Travassos NF; Salomão R; Colombo AL
Diagn Microbiol Infect Dis; 2007 Apr; 57(4):399-404. PubMed ID: 17240110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
